Report Detail

Pharmaceuticals Generalizedized Anxiety Disorder (GAD) - Pipeline Insight, 2020

  • RnM4222430
  • |
  • 09 October, 2020
  • |
  • Global
  • |
  • 65 Pages
  • |
  • DelveInsight
  • |
  • Pharmaceuticals


    Executive Summary

      Generalized Anxiety Disorder: Overview

        • Causes

          • Mechanism of Action

            • Signs and Symptoms

              • Diagnosis

                • Disease Management

                  Pipeline Therapeutics

                    • Comparative Analysis

                      Therapeutic Assessment

                        • Assessment by Product Type

                          • Assessment by Stage and Product Type

                            • Assessment by Route of Administration

                              • Assessment by Stage and Route of Administration

                                • Assessment by Molecule Type

                                  • Assessment by Stage and Molecule Type

                                    Generalized Anxiety Disorder – DelveInsight’s Analytical Perspective

                                      In-depth Commercial Assessment

                                        • Generalized Anxiety Disorder companies’ collaborations, Licensing, Acquisition -Deal Value Trends

                                          Generalized Anxiety Disorder Collaboration Deals

                                            • Company-Company Collaborations (Licensing / Partnering) Analysis

                                              • Company-University Collaborations (Licensing / Partnering) Analysis

                                                Late Stage Products (Phase III)

                                                  • Comparative Analysis

                                                    Vilazodone: AbbVie

                                                      • Product Description

                                                        • Research and Development

                                                          • Product Development Activities

                                                            Drug profiles in the detailed report…..

                                                              Pre-clinical and Discovery Stage Products

                                                                • Comparative Analysis

                                                                  Duloxetine oral suspension: OWP Pharmaceuticals

                                                                    • Product Description

                                                                      • Research and Development

                                                                        • Product Development Activities

                                                                          Drug profiles in the detailed report…..

                                                                            Inactive Products

                                                                              • Comparative Analysis

                                                                                Generalized Anxiety Disorder Key Companies

                                                                                  Generalized Anxiety Disorder Key Products

                                                                                    Generalized Anxiety Disorder- Unmet Needs

                                                                                      Generalized Anxiety Disorder- Market Drivers and Barriers

                                                                                        Generalized Anxiety Disorder- Future Perspectives and Conclusion

                                                                                          Generalized Anxiety Disorder Analyst Views

                                                                                            Generalized Anxiety Disorder Key Companies


                                                                                              DelveInsight’s, “Generalized Anxiety Disorder (GAD) – Pipeline Insight, 2020,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
                                                                                              Geography Covered
                                                                                              • Global coverage
                                                                                              Generalized Anxiety Disorder Understanding
                                                                                              Generalized Anxiety Disorder (GAD): Overview
                                                                                              Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. People with generalized anxiety disorder (GAD) display excessive anxiety or worry, most days for at least 6 months, about a number of things such as personal health, work, social interactions, and everyday routine life circumstances. The fear and anxiety can cause significant problems in areas of their life, such as social interactions, school, and work.
                                                                                              • Generalized anxiety disorder symptoms include:
                                                                                              • Feeling restless, wound-up, or on-edge
                                                                                              • Being easily fatigued
                                                                                              • Having difficulty concentrating; mind going blank
                                                                                              • Being irritable
                                                                                              • Having muscle tension
                                                                                              • Difficulty controlling feelings of worry
                                                                                              • Having sleep problems, such as difficulty falling or staying asleep, restlessness, or unsatisfying sleep
                                                                                              Generalized Anxiety Disorder is diagnosed with a mental health screening that a primary care provider can perform. They will ask questions about symptoms and how long the patient have had them. They can refer the patients to a mental health specialist, such as a psychologist or psychiatrist. If the primary care provider suspects that a medical condition or substance abuse problem is causing anxiety, they may perform more tests. These may include:
                                                                                              • blood tests, to check hormone levels that may indicate a thyroid disorder
                                                                                              • urine tests, to check for substance abuse
                                                                                              • gastric reflux tests, such as an X-ray of your digestive system or an endoscopy procedure to look at your esophagus, to check for GERD
                                                                                              • X-rays and stress tests, to check for heart conditions
                                                                                              Treatment for Generalized Anxiety Disorder most often includes a combination of medication and cognitive behavioral therapy.
                                                                                              • Cognitive behavioral therapy: People being treated for anxiety disorders often take part in this type of therapy, in which they learn to recognize and change thought patterns and behaviors that lead to anxious feelings.
                                                                                              • Medications: These aren’t a cure, but they can help ease symptoms. The drugs most often used to treat GAD in the short term (since they can be addictive, are sedating, and can interfere with memory and attention) are from a group of drugs called benzodiazepines.
                                                                                              o Common benzodiazepines include alprazolam (Xanax), chlordiazepoxide Hcl (Librium), diazepam (Valium), and lorazepam (Ativan).
                                                                                              Generalized Anxiety Disorder Emerging Drugs Chapters
                                                                                              This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
                                                                                              Generalized Anxiety Disorder Emerging Drugs
                                                                                              • Vilazodone: AbbVie; Allergan; m8 Pharmaceuticals
                                                                                              Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). Vilazodone has been speculated to have three potential benefits including faster onset of action, greater efficacy, and better tolerability owning to its SPARI properties.
                                                                                              Further product details are provided in the report……..
                                                                                              Generalized Anxiety Disorder: Therapeutic Assessment
                                                                                              This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:
                                                                                              • Major Players in Generalized Anxiety Disorder
                                                                                              There are approx. 8+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AbbVie, Allergan, m8 Pharmaceuticals etc.
                                                                                              DelveInsight’s report covers around 8+ products under different phases of clinical development like
                                                                                              • Mid-stage products (Phase II and Phase I/II)
                                                                                              • Early-stage products (Phase I/II and Phase I) along with the details of
                                                                                              • Pre-clinical and Discovery stage candidates
                                                                                              • Discontinued & Inactive candidates

                                                                                              • Route of Administration
                                                                                              Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
                                                                                              • Intravenous
                                                                                              • Oral
                                                                                              • Intramuscular

                                                                                              • Molecule Type
                                                                                              Products have been categorized under various Molecule types such as
                                                                                              • Small molecules
                                                                                              • Peptides

                                                                                              • Product Type
                                                                                              Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

                                                                                              Generalized Anxiety Disorder: Pipeline Development Activities
                                                                                              The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.
                                                                                              Pipeline Development Activities
                                                                                              The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.

                                                                                              Report Highlights
                                                                                              • The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.
                                                                                              Generalized Anxiety Disorder Report Insights
                                                                                              • Generalized Anxiety Disorder Pipeline Analysis
                                                                                              • Therapeutic Assessment
                                                                                              • Unmet Needs
                                                                                              • Impact of Drugs
                                                                                              Generalized Anxiety Disorder Report Assessment
                                                                                              • Pipeline Product Profiles
                                                                                              • Therapeutic Assessment
                                                                                              • Pipeline Assessment
                                                                                              • Inactive drugs assessment
                                                                                              • Unmet Needs

                                                                                              Key Questions
                                                                                              Current Treatment Scenario and Emerging Therapies:
                                                                                              • How many companies are developing Generalized Anxiety Disorder drugs?
                                                                                              • How many Generalized Anxiety Disorder drugs are developed by each company?
                                                                                              • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?
                                                                                              • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?
                                                                                              • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
                                                                                              • What are the clinical studies going on for Generalized Anxiety Disorder and their status?
                                                                                              • What are the key designations that have been granted to the emerging drugs?
                                                                                              Key Players
                                                                                              • AbbVie
                                                                                              • Allergan
                                                                                              • m8 Pharmaceuticals
                                                                                              • OWP Pharmaceuticals
                                                                                              Key Products
                                                                                              • Vilazodone
                                                                                              • Duloxetine oral suspension

                                                                                              Get latest Market Research Reports on Generalizedized Anxiety Disorder (GAD) . Industry analysis & Market Report on Generalizedized Anxiety Disorder (GAD) is a syndicated market report, published as Generalizedized Anxiety Disorder (GAD) - Pipeline Insight, 2020. It is complete Research Study and Industry Analysis of Generalizedized Anxiety Disorder (GAD) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                              Last updated on

                                                                                              REPORT YOU MIGHT BE INTERESTED

                                                                                              Purchase this Report

                                                                                              Credit card Logo

                                                                                              Related Reports

                                                                                              Reason to Buy

                                                                                              Request for Sample of this report